MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress Meeting Abstract
| Authors: | Strickler, J.; Nakamura, Y.; Shitara, K.; Catenacci, D.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Lee, J.; Van Cutsem, E.; Chung, H.; Tabernero, J.; Yoshino, T.; Siena, S.; Garrido-Mayor, J.; Palanca-Wessels, M.; Xie, D.; Marshall, J. |
| Abstract Title: | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress |
| Meeting Title: | ESMO 23rd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2021 Jun 30-Jul 3 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-07-01 |
| Start Page: | S159 |
| Language: | English |
| ACCESSION: | WOS:000670004200173 |
| DOI: | 10.1016/j.annonc.2021.05.229 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-174 -- Source: Wos |
